Evaluation of the lung function in cancer patients undergoing to chemotherapy

• Autor(a) principal: Vione, Caroline Heemann
• Data de Publicação: 2016
• Outros Autores: Wagner, Litiele Evelin, Benelli, Thaís Ermelinda Schulz, Hopp, Marciele Silveira, Cardoso, Dannuey Machado, Paiva, Dulciane Nunes, Albuquerque, Isabella Martins de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista de Epidemiologia e Controle de Infecção
• Texto Completo: https://online.unisc.br/seer/index.php/epidemiologia/article/view/7970

Background and Objective: Some neoplastic agents used in cancer treatment cause pulmonary toxicity and other important adverse effects, therefore, the present study aimed to evaluate the presence of obstructive lung disease (OLD), restrictive lung disease (RLD) or mixed in patients 2 with cancer undergoing chemotherapy. Method: This is a cross-sectional and descriptive study that evaluated patients diagnosed with cancer and undergoing chemotherapy using Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Cyclophosphamide, Fluorouracil and Vincristine, being excluded those diagnosed with lung cancer. Realized pulmonary function test byspirometric analysis (EasyOne®, Switzerland) in patients who started chemotherapy for over 30 days, it was evaluated the Forced Vital Capacity (FVC), forced expiratory volume in one second FVC (FEV1), forced expiratory flow between 25-75% of FVC (FEF25-75 %) and the FEV1 / FVC Relation before the chemotherapy session. Results: Sample (n = 18) composed of cancer patients with average age of 49.28±9.90 years and 26.49±5.67 kg/m2 on which 44.4% had normal spirometry standard, 27.8% had OLD, 16.7% presented RLD and 11.1% presented mixed respiratory disorder. Conclusion: Thechemotherapy resulted in obstructive pulmonary disease, restrictive and mixedin patients with leukemia, breast cancer and Hodgkin's lymphoma not specific evaluated.